Explore the Agenda
8:00 am Check In & Morning Coffee
8:50 am Chair’s Opening Remarks
Overcoming Regulatory Hurdles & Establishing Beneficial Partnerships to Advance Best-in-Class mRNA Drugs to Patients Faster
9:00 am Fireside Discussion: A Regulatory Perspective on the Complexity of Global Policy & Market Dynamics Towards the First mRNA Therapeutic Approval
The regulatory landscape for mRNA is changing and becoming increasingly complex with new products in clinical development from cancer immunotherapies to cell therapies. Drug developers require further clarity and collaboration with the regulatory authorities to reach their milestones. This panel will feature regulatory and policy experts who will share their understanding of getting new mRNA products into market.
- How are the current global policies and government decisions impacting the mRNA industry?
- How as a community can we work with the regulators to reduce impact on development timelines whilst improving trust with the global community?
- What will it take to see the next therapy successfully achieve market authorization and which indications or innovations will lead to this effort?
10:00 am Panel Discussion: The mRNA Industry Outlook – A Panel on Future Biopharma Partnerships & Collaborations
The biopharmaceutical sector continues to seek new opportunities to leverage mRNA technology and thrives on strategic alliances, which allow for cross-functional sharing of knowledge, skills, and experience across different disciplines to truly advance mRNA drugs to patients faster. Hear first-hand how biopharma business development leaders and investors are taking their time to evaluate novel innovations and building new collaborations.
- Leveraging the past experiences of recent deals, collaborations and acquisitions in mRNA-LNP platforms to inform future risk and decision-making strategies
- Where do you see potential white spaces that mRNA can fill within this sector or indications more specifically?
- What data is required and how far does an asset have to progress towards future investment or acquisition success?
11:00 am Morning Break & Networking
Discovery
Trailblazing Novel Target Discovery with Circular Platforms to Improve Durability & Cost
11:30 am A Novel Room Temperature Stable Circular RNA Platform for Production of Proteins & Peptides to Treat Different DiseasesA Novel Room Temperature Stable Circular RNA Platform for Production of Proteins & Peptides to Treat Different Diseases
Chief Executive Officer, Circurna
- Showcasing the development of a circular RNA platform that is room temperature stable, durable for a long period of time in vivo after administration and results in very high protein production starting shortly after administration
- Administrating circular RNA using microneedle patches resulting in preferential targeting of the circular RNA to the cells that produce protein in vivo to treat cancers, autoimmune, fibrosis and other diseases and will be used on human patients as part of Circurna’s first Phase I clinical trial in early 2027
- Developing a novel and industry leading purification manufacturing protocol that results in high circularization, high yield, high purity at a low cost
12:00 pm Circular RNA: From Promise to Reality
CEO, RNAvate
- Designing next-generation Circular RNA
- Delineating the challenges of developing a circular RNA platform
- Highlighting the implications for the pipeline and opportunities for the circular RNA field
Pre-Clinical & Clinical Development
Manufacturing & CMC
12:30 pm General Lunch Break & Networking
12:30 pm Private Hosted Lunch (By Invitation Only)
Discovery
Biotech Showcase: Bridging Novel mRNA Platforms with AI Tools to Generate Target & Cell Specific Data
1:30 pm Evolution-Inspired Next-Gen mRNA Therapeutics for Longevity
CEO, CaVos Biotherapeutics
- Evolutionary AI Platform: Discovery of first-in-class therapeutic mRNA leads converged in long-lived species
- In Vitro Success: Hit-to-multicistronic mRNA translation, showcasing crosstalk in fibrosis modulation
- Next Steps: Advancing mRNA and LNP therapeutics toward IND
2:00 pm RNARISE: A Non-Viral Self-Amplifying RNA Platform Technology for Therapeutics
CEO, Cambridge Medixine Ltd
- Presenting CamMed’s AI-assisted pipeline to discover eukaryotic RNA replicases
- Showcasing a proof-of-concept for CamMed’s RNARISE(TM) data: Biochemistry and cell data
- Highlighting the CamMed Pipeline: MPSIIIA/B (Mucchopolysaccharidosis) protein replacement therapy
Pre-Clinical & Clinical Development
Manufacturing & CMC
2:30 pm Afternoon Break & Networking
Plenary Session
Advancing Clinical Development of mRNA Cancer Therapies Towards Effective & Patient Specific Treatments
3:00 pm mRNA-Based Therapeutics for Targeting Neoantigens & Overexpressed Antigens in Children & Young Adults with High-Risk Brain Tumours
- Introducing the Brain tumor antigen landscape and opportunities for personalized mRNA Therapeutics
- Presenting the PAEDNEOVAX trial phase I/II clinical trial evaluating a personalised mRNA vaccine in children and adolescents with relapsed/refractory brain tumours (including medulloblastoma, ependymoma and high grade glioma) and newly diagnosed Diffuse Midline Glioma (DMG)
- Unveiling the strategy to provide the mRNA therapeutic on time for treatment and preliminary results
3:30 pm A Review of the mRNA-Based Drug Development Landscape
- An overview of the preclinical and clinical landscape
- A review of recent developments within the commercial landscape
- Insights into the future of mRNA therapies including therapies to watch
4:00 pm Advancing Cancer Immunotherapy with Synthetic Self-Replicating mRNA Technology
- Spotlighting mRNA technology in medicine
- Highlighting key use cases in immuno-oncology
- Presenting use cases in immune cell engineering